Abstract Number: 463 • 2013 ACR/ARHP Annual Meeting
An Indirect Comparisons Analysis Between Biologic Disease Modifiers in The Treatment Of Rheumatoid Arthritis To Evaluate For Efficacy and Safety
Background/Purpose: There are primarily six groups of biologic disease modifiers (BDM) for treatment of rheumatoid arthritis (RA): tumor necrosis factor inhibitors (infliximab (IFX), etanercept (ETN),…